Historical Valuation
Novartis AG (NVS) is now in the Fair zone, suggesting that its current forward PE ratio of 15.15 is considered Fairly compared with the five-year average of 12.93. The fair price of Novartis AG (NVS) is between 122.57 to 174.07 according to relative valuation methord.
Relative Value
Fair Zone
122.57-174.07
Current Price：142.75
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Novartis AG (NVS) has a current Price-to-Book (P/B) ratio of 6.00. Compared to its 3-year average P/B ratio of 4.85 , the current P/B ratio is approximately 23.60% higher. Relative to its 5-year average P/B ratio of 4.22, the current P/B ratio is about 42.00% higher. Novartis AG (NVS) has a Forward Free Cash Flow (FCF) yield of approximately 7.38%. Compared to its 3-year average FCF yield of 7.06%, the current FCF yield is approximately 4.50% lower. Relative to its 5-year average FCF yield of 6.94% , the current FCF yield is about 6.35% lower.
P/B
Median3y
4.85
Median5y
4.22
FCF Yield
Median3y
7.06
Median5y
6.94
Competitors Valuation Multiple
AI Analysis for NVS
The average P/S ratio for NVS competitors is 4.32, providing a benchmark for relative valuation. Novartis AG Corp (NVS.N) exhibits a P/S ratio of 4.73, which is 9.37% above the industry average. Given its robust revenue growth of 9.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for NVS
1Y
3Y
5Y
Market capitalization of NVS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NVS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NVS currently overvalued or undervalued?
Novartis AG (NVS) is now in the Fair zone, suggesting that its current forward PE ratio of 15.15 is considered Fairly compared with the five-year average of 12.93. The fair price of Novartis AG (NVS) is between 122.57 to 174.07 according to relative valuation methord.
What is Novartis AG (NVS) fair value?
NVS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Novartis AG (NVS) is between 122.57 to 174.07 according to relative valuation methord.
How does NVS's valuation metrics compare to the industry average?
The average P/S ratio for NVS's competitors is 4.32, providing a benchmark for relative valuation. Novartis AG Corp (NVS) exhibits a P/S ratio of 4.73, which is 9.37% above the industry average. Given its robust revenue growth of 9.00%, this premium appears unsustainable.
What is the current P/B ratio for Novartis AG (NVS) as of Jan 09 2026?
As of Jan 09 2026, Novartis AG (NVS) has a P/B ratio of 6.00. This indicates that the market values NVS at 6.00 times its book value.
What is the current FCF Yield for Novartis AG (NVS) as of Jan 09 2026?
As of Jan 09 2026, Novartis AG (NVS) has a FCF Yield of 7.38%. This means that for every dollar of Novartis AG’s market capitalization, the company generates 7.38 cents in free cash flow.
What is the current Forward P/E ratio for Novartis AG (NVS) as of Jan 09 2026?
As of Jan 09 2026, Novartis AG (NVS) has a Forward P/E ratio of 15.15. This means the market is willing to pay $15.15 for every dollar of Novartis AG’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Novartis AG (NVS) as of Jan 09 2026?
As of Jan 09 2026, Novartis AG (NVS) has a Forward P/S ratio of 4.73. This means the market is valuing NVS at $4.73 for every dollar of expected revenue over the next 12 months.